Nutrition Research and Practice

  • 제2권2호
  • /
  • Pages.55-61
  • /
  • 2008
  • /
  • 1976-1457(pISSN)
  • /
  • 2005-6168(eISSN)
한국영양학회 (The Korean Nutrition Society)
권호 표지

Dose-response assessment of the anti-cancer efficacy of soy isoflavones in dimethylhydrazine-treated rats fed 6% fructooligosaccharide

  • Published : 2008.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

Abstract

We investigated the combinatorial effects of different doses of dietary soy isoflavones (SI) and fructooligosaccharide (FOS) in a rat model of colon cancer. We hypothesized that increased bioavailability of SI metabolites due to dietary FOS may increase production of bioactive equol and affect colon carcinogenesis in a dose-dependent manner. Sprague-Dawley male rats were injected with 12-dimethylhydrazine (DMH) and were providec experimental diets that contained 0, 10, 50, 150, or 500 mg SI per kg of diet and 6% FOS for 12 weeks. The number of aberrant crypt foci (ACF) and the expression of cyclooxygenase-2 (COX-2) in colonic tissues were significantly decreased in the 6% FOS-fed groups compared to the control group. Gut transit time and fecal pH were significantly lower, and fecal concentrations of bifidobacteria were increased with 6% FOS. However, dietary SI supplementation in combination with 6% dietary FOS did not affect ACF formation or COX-2 expression. Plasma equol concentrations were dose-dependently increased by supplementation of SI up to 500 mg/kg of diet. In conclusion, SI supplementation up to 500 mg/kg of diet appeared to have no additive beneficial effects in rats with chemically-induced colon cancer that were fed 6% FOS, although plasma equol was dose-dependently increased.

Keywords

References

  1. Adlercreutz H (1995). Phytoestrogens: epidemiology and a possible role in cancer protection. Environ Health Perspect 103:103-112 https://doi.org/10.1289/ehp.95103s9103
  2. American Institute of Nutrition (1993). Report of the ad hoc committee on standards for nutrition studies. J Nutr 123:1939-1951 https://doi.org/10.1093/jn/123.11.1939
  3. Atkinson C, Berman S, Humbert O & Lampe JW (2004). In vitro incubation of human feces with daidzein and antibiotics suggests interindividual differences in the bacteria responsible for equol production. J Nutr 134:596-599
  4. Atkinson C, Frankenfeld CL & Lampe JW (2005). Gut bacterial metabolism of soy isoflavone daidzein: Exploring the relevance to human health. Exp Biol Med 230:155-170 https://doi.org/10.1177/153537020523000302
  5. Bird RP (1995). Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 93:55-71 https://doi.org/10.1016/0304-3835(95)03788-X
  6. Bird RP & Good CK (2000). The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol Lett 112-113:395-402 https://doi.org/10.1016/S0378-4274(99)00261-1
  7. Birt DF, Hendrich S & Wang W (2001). Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther 90:157-177 https://doi.org/10.1016/S0163-7258(01)00137-1
  8. Brouwers E, L'homme R, Al-Maharik N, Lapck O, Hampl R, Wahala K, Mikola H & Adlercreutz H. (2003). Time-resolved fluoroimmunoassay for equol in plasma and urine. J Steroid Biochem Mol Biol 84:577-587 https://doi.org/10.1016/S0960-0760(03)00071-2
  9. Cho JW, Park K, Kweon GR., Jang BC, Baek WK, Suh MH, Kim CW, Lee KS & Suh SI (2005). Curcumin inhibits the expression of COX-2 in UVB-irradiated human keratinocytes (HaCaT) by inhibiting activation of AP-1: p38 MAP kinase and JNK as potential upstream targets. Exp Mol Med 37:186-192 https://doi.org/10.1038/emm.2005.25
  10. Cotterchio M, Boucher BA, Manno M, Gallinger S, Okey A & Harper P (2006). Dietary phytoestrogen intake is associated with reduced colorectal cancer risk. J Nutr 136:3046-3053
  11. Cummings JH & Bingham SA (1998). Diet and the prevention of cancer. BMJ 317:1636-1640 https://doi.org/10.1136/bmj.317.7173.1636
  12. Daly KT, Tracy AC, Malik M, Wang T, Francke-Carroll S & Magnuson BA (2007). Enhanced estrogenic responses and sensitivity to azoxymethane following dietary soy isoflavone supplementation in older female rats. Food Chem Toxicol 45:628-637 https://doi.org/10.1016/j.fct.2006.10.021
  13. Guo JY, Li X, Browning J, Rottinghaus GE, Lubahn DB, Constantinou A, Bennink M, & MacDonald R (2004). Dietary soy isoflavones and estrone protect ovariectomized ERoKO and wild-type mice from carcinogen-induced colon cancer. J Nutr 134:179-182
  14. Jacoby RF, Seibert K, Cole CE, Kelloff G & Lubet RA (2000). The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60:5040-5044
  15. Ji GE, Kim IH, & Lee SK (1994). Investigation of selective medium for isolation and enumeration of Bacteriodes sp. from the feces of the Korean people. Korean Journal of Food Science and Technology 26:295-299
  16. Khalil DA, Lucas EA., Smith BJ, Soung DY, Devareddy L, Juma S, Akhter MP, Recker AR & Arjmandi BH (2005). Soy isoflavones may protect against archidectomy-induced bone loss in aged male rats. Calcif Tissue Int 76: 50-62 https://doi.org/10.1007/s00223-004-0040-1
  17. Lim CC, Ferguson LR, & Tannock GW (2005). Dietary fibers as "prebiotics" : implications for colorectal cancer. Mol Nutr Food Res 49:609-619 https://doi.org/10.1002/mnfr.200500015
  18. McClain RM, Wolzm E, Davidovish A, Pfannkuch F, Edwards JA, & Bausch J (2006). Acute, subchronic and chronic safety studies with genistein in rats. Food Chem Taxicol 44:56-80 https://doi.org/10.1016/j.fct.2005.05.021
  19. Mathey J, Puel S, Kati-Coulibaly S, Bennetau-Pelissero C, Davicco MJ, Lebecque P, Horcajada MN & Coxam V (2004). Fructooligosaccharides maximize bone-sparing effects of soy isoflavoneenriched diet in the ovariectomized rat. Calcif Tissue Int 75 :169-179 https://doi.org/10.1007/s00223-004-0128-7
  20. Messina M & Bennink M (1998). Soyfoods, isoflavones and risk of colonic cancer: a review of the in vitro and in vivo data. Baillieres Clin Endocrinol Metab 12:707-728 https://doi.org/10.1016/S0950-351X(98)80012-8
  21. Nielsen ILF & Williamson G (2007). Review of the factors affecting bioavailability of soy isoflavones in humans. Nutr Cancer 57:1-10 https://doi.org/10.1080/01635580701267677
  22. Ohta A, Uehara M, Sakai K, Takasaki M, Adlercreutz H, Morohashi T & Ishimi Y (2002). A combination of dietary fructooligosaccharides and isoflavone conjugates increases femoral bone mineral density and equol production in ovariectomized mice. J Nutr 132:2048-2054
  23. Onoue M, Kado S, Sakaitani Y, Uchida K & Morotomi M (1997). Specific species of intestinal bacteria influence the induction of aberrant crypt foci by 1,2-dimethylhydrazine in rats. Cancer Lett 113:179-186 https://doi.org/10.1016/S0304-3835(97)04698-3
  24. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF & Taketo MM (1996). Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 87:803-809 https://doi.org/10.1016/S0092-8674(00)81988-1
  25. Picherit C, Coxam V, Bennetau-Pelissero C, Kati-coulibaly S, Davicco MJ, Lebecque P & Barlet JP (2000). Daidzein is more efficient than genistein in preventing ovariectomy-induced bone loss in rats. J Nutr 130:1675-1681
  26. Pierre F, Perrin P, Champ M, Bomet F, Meflah K & Menanteau J (1991). Short-chain fructo-oligosaccharides reduce the occurrence of colon tumors and develop gut-associated lymphoid tissue in Min mice. Cancer Res 57:225-228
  27. Setchell KDR, Brown NM & Lydeking-Olsen E (2002). The clinical importance of the metabolite Equol - A clue to the effectiveness of soy and its isoflavones. J Nutr 132:3577-3584
  28. Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ & Murray FE (1999). The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282: 1254-1257 https://doi.org/10.1001/jama.282.13.1254
  29. Sorensen IK, Kristiansen E, Mortensen A, Nicolaisen GM, Wijnands JAH, van Kranen HJ, & van Kreijl CF (1998). The effect of soy isoflavones on the development of intestinal neoplasia in $Apc^{Min}$ mouse. Cancer Lett 130:217-225 https://doi.org/10.1016/S0304-3835(98)00139-6
  30. Sung HY & Choi YS (2008). Fructooligosaccharide and soy isoflavone suppress colonic aberrant crypt foci and cyclooxygenase-2 expression in dimethylhydrazine-treated rats, J Med Food 11:78-85 https://doi.org/10.1089/jmf.2007.003
  31. Sung HY, Lim YJ & Choi YS (2006). Soy isoflavones do not alter the effects of fructooligosaccharide on the intestinal ecosystem of colon-cancer model rats. Food Sci Biotechnol 15:931-936
  32. Uehara M, Ohta A, Sakai K, Suzuki K, Watanabe S & Adlercreutz H (2001). Dietary fructooligosaccharides modify intestinal bioavailability of a single dose of genistein and daidzein and affect their urinal)' excretion and kinetics in blood of rats, J Nutr 131 :787-795
  33. WHO (2003). Technical Report Series 916, Diet, Nutrition and the Prevention of Chronic Diseases. pp.95-104, World Health Organization, Geneva, Switzerland